AbbVie suggests new interpretation of ‘patient’ is necessary in 340B lawsuitnews2026-04-09T18:18:32+00:00April 9th, 2026|Endpoints News|
Roche dips into DACs with existing partner C4 Therapeutics for $20M upfrontnews2026-04-09T14:17:59+00:00April 9th, 2026|Endpoints News|
PhRMA head Steve Ubl to step down at end of yearnews2026-04-08T16:15:29+00:00April 8th, 2026|Endpoints News|
Insmed shelves Brinsupri in skin disease after mid-stage flopnews2026-04-08T10:06:51+00:00April 8th, 2026|Endpoints News|
Did Eli Lilly just strike another gold mine?news2026-04-07T19:29:41+00:00April 7th, 2026|Endpoints News|
Study suggests $35 monthly insulin cap has increased patient accessnews2026-04-07T18:52:01+00:00April 7th, 2026|Endpoints News|
White House adds AbbVie’s Humira to TrumpRx alongside cheaper biosimilarsnews2026-04-07T18:10:11+00:00April 7th, 2026|Endpoints News|
Terns sold to Merck for 13% lower than pharma’s initial offer because of clinical datanews2026-04-07T15:30:06+00:00April 7th, 2026|Endpoints News|
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCsnews2026-04-07T12:17:00+00:00April 7th, 2026|Endpoints News|
BioNTech to shutter Singapore HQ after ‘comprehensive review’news2026-04-07T11:20:12+00:00April 7th, 2026|Endpoints News|
